Lipoprotein glycation and glycoxidation: Their importance in diabetes mellitus;La glicacion y glicoxidacion de las lipoproteinas: Su importancia en la diabetes mellitus

Medicina

Volumn 60, Issue 5, 2000, Pages 645-656

  Actis Dato, Sara M ^a   Rebolledo, Oscar R ^a,b  

^a UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^b University of La Plata CONICET   (Argentina)

Author keywords

Atherosclerosis; Diabetes; LDL glycoxidation; Lipoprotein glycoxidation; Non enzymatic glycation

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; GLYCOSYLATION; HUMAN; HYPERGLYCEMIA; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY; REVIEW;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; GLUCOSE; GLYCOSYLATION; HUMANS; HYPERGLYCEMIA; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; OXIDATIVE STRESS;

EID: 5844274859     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Pyörälä K, Laakso M, Uusitupa M. Diabetes and arteriosclerosis: an epidemiologic view. Diabetes Metab Rev 1987; 3: 463-524.
2. Laakso M, Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Rev 1997; 5: 294-315.
3. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-5.
4. Taskinen MR. Quantitative and Quantitative lipoprotein abnormalities in diabetes mellitus. Diabetes 1992; 41 (suppl 2): 12-7.
5. Hanefeld M, Kurktchiev T. Plasma lipids in diabetics. En: Schwartz CJ, Born GVR (eds). New horizons in diabetes mellitus and cardiovascular disease. London: Current Science, 1995; p 89-95.
6. Lopes-Virella MF, Klein RL, Virella G. Modification of lipoproteins in diabetes. Diabetes Metab Rev 1996; 12: 69-90.
7. Lyons TJ. Lipoprotein glycation and its metabolic consequences. Diabetes 1992; 41 (suppl 2): 67-73.
8. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-12.
9. The DCCT research group: the effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial. N Engl J Med 1993; 329: 977-86.
10. Vlassara H, Brownlee M, Cerami A. Nonenzymatic glycosylation: role in the pathogenesis of diabetic complications. Clin Chem 1986; 32 (No 10-B): B37-B41.
11. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes care 1992; 15: 1835-42.
12. Bucala R. Lipid and lipoprotein advanced glycosylation in diabetic cardiovascular disease. En: Schwartz CJ, Born GVR (eds). New horizons in diabetes mellitus and cardiovascular disease. London: Current Science, 1995; p 103-10.
13. Hunt JV, Smith ChCT, Wolff SP. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 1990; 39: 1420-4.
14. Lyons TJ, Jenkins AJ. Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis. Diabetes Rev 1997; 5: 365-91.
15. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications. Diabetes 1999; 48: 1-9.
16. Palinski W, Witztum JL. Oxidative stress and diabetes mellitus. En: Schwartz CJ, Born GVR (eds). New horizons in diabetes mellitus and cardiovascular disease. London: Current Science, 1995, p 111-23.
17. Schleicher E, Deufel T, Wieland OH. Non-enzymatic glycosylation of human serum lipoproteins. FEBS Lett 1981; 129: 1-4.
18. 11, B, C1 and E are glucosylated in hyperglycemic diabetic subjects. Diabetes 1985; 34: 452-61.
19. Kim HJ, Kurup IV. Nonenzymatic glycosylation of human plasma LDL; evidence for in vitro and in vivo glucosylation. Metabolism 1982; 31: 348-53.
20. Lyons TJ, Patrick JS, Baynes JW, Colwell JA, Lopes-Virella MF. Glycosylation of LDL in patients with type I diabetes: correlations with other parameters of glycaemic control. Diabetologia 1986; 29: 685-9.
21. Bucala R, Makita Z, Koschinsky T, Cerami A, Viassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993; 90: 6434-8.
22. Passarelli M, Catanozi S, Nakandakare ER, et al. Plasma lipoproteins from patients with poorly controlled diabetes mellitus and in vitro glycation of lipoproteins enhance the transfer rate of cholesteryl ester from HDL to apo-B-containing lipoproteins. Diabetologia 1997; 40: 1085-93.
23. Bucala R, Makita Z, Vega G, et al. Modification of LDL by advanced glycation endproducts contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994; 91: 9441-5.
24. Klein RL, Laimins M, Lopes-Virella MF. Isolation, characterization and metabolism of the glycated and nonglycated subfractions of LDL isolated from type I diabetic patients and nondiabetic subjects. Diabetes 1995; 44: 1093-8.
25. Sobenin IA, Tertov W, Orekhov AN. Atherogenic modified LDL in diabetes. Diabetes 1996; 45 (suppl 3): S35-S39.
26. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495-506.
27. Haffner SM. LDL size in patients with NIDDM and the insulin resistance syndrome. En: Schwartz CJ, Born GVFR (eds). New horizons in diabetes mellitus and cardiovascular disease. London: Current Science, 1995, p 96-102.
28. Sasaki J, Cottam GL. Glycation of LDL decreases its ability to interact with high-affinity receptors of human fibroblasts in vitro and decreases its clearance from rabbit plasma in vivo. Biochim Biophys Acta 1982; 713: 199-207.
29. Gonen B, Baenziger J, Schonfeld G, Jacobsen D, Farrar P. Non-enzymatic glycation of LDL in vitro. Diabetes 1981 ; 30: 875-8.
30. Witztum JL, Mahoney EM, Branks MJ, Fisher M, Elam R, Steinberg D. Nonenzymatic glucosylation of LDL alters its biologic activity. Diabetes 1982; 31: 283-91.
31. Steinbrecher UP, Witztum JL. Glucosylation of LDL to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 1984; 33: 130-4.
32. Bucala R, Mitchell R, Arnold K, Innerarity Th, Vlassara H, Cerami A. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the LDL receptor. J Biol Chem 1995; 270: 10828-32.
33. Wang X, Bucala R, Milne R. Epitopes close to the apolipoprotein B LDL receptor-binding site are modified by advanced glycation end products. Proc Natl Acad Sci USA 1998; 95: 7643-7.
34. Stitt AW, Bucala R, Vlassara H. Atherogenesis and advanced glycation: promotion, progression, and prevention. Ann N Y Acad Sci 1997; 811: 115-29.
35. Lopes-Virella MF, Klein RL, Lyons TJ, Stevenson HC, Witztum JL. Glycosylation of LDL enhances cholesteryl ester synthesis in human monocyte-derived macrophages. Diabetes 1988; 37: 550-7.
36. Lyons TJ, Klein RL, Baynes JW, Stevenson HC, Lopes-Virella MF. Stimulation of cholesteryl ester synthesis in human monocyte-derived macrophages by LDL from type I (insulin-dependent) diabetic patients: the influence of non-enzymatic glycation of LDL. Diabetologia 1987; 30: 916-23.
37. Dobrian A, Simionescu M. Irreversibly glycated albumin alters the physico-chemical characteristics of LDL of normal and diabetic subjects. Biochim Biophys Acta 1995; 1270: 26-35.
38. Dobrian A, Lazar V, Tirziu D, Simionescu M. Increased macrophage uptake of irreversibly glycated albumin modified-LDL of normal and diabetic subjects is mediated by non-saturable mechanisms. Biochim Biophys Acta 1996; 1317: 5-14.
39. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation products on collagen covalently trap LDL. Diabetes 1985; 34: 938-41.
40. Edwards IJ, Wagner JD, Litwak KN, Cefalu WT, Rudel LL. Diabetes-induced modification of plasma LDL leads to increased interaction with arterial proteoglycans. Diabetes 1997; 46: 45 A.
41. Nakamura Y, Horii Y, Nishino T, et al. Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993; 143: 1649-56.
42. Steinbrecher UP, Witztum JL, Parthasarathy S, Steinberg D. Decrease in reactive amino groups during oxidation or endothelial cell modification of LDL. Correlation with changes in receptor-mediated catabolism. Arteriosclerosis 1987; 7: 135-43.
43. Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 1990; 173: 932-9.
44. ε-(carboxymethyl) lysine (CML), is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996; 271: 9982-6.
45. Requena JR, Ahmed MU, Fountain CW, et al. Carboxy-methylethanolamine: a biomarker of phospholipid modification during the Maillard reaction in vivo. J Biol Chem 1997, 272: 17473-9.
46. Kobayashi K, Watanabe J, Umeda F, Nawata H. Glycation accelerates the oxidation of LDL by copper ions. Endocr J 1995; 42: 461-5.
47. Sakurai T, Kimura S, Nakano M, Kirnura H. Oxidative modifications of glycated LDL in the presence of iron. Biochem Biophys Res Commun 1991 ; 177: 433-9.
48. Tsai EC, Hirsch IB, Brunzell JD, Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 1994; 43: 1010-4.
49. Jenkins AJ, Klein RL, Chassereau ChN, Hermayer KL, Lopes-Virella MF. LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes 1996, 45: 762-7.
50. Bellomo G, Maggi E, Poli M, Agosta FG, Bollati P, Finardi G. Autoantibodies against oxidatively modified LDL in NIDDM. Diabetes 1995; 44: 60-6.
51. Brownlee M, Pongor S, Cerami A. Covalent attachment of soluble proteins by non-enzymatically glycosylated collagen: role in the in situ formation of immune complexes. J Exp Med 1983, 158: 1739-44.
52. Lopes-Virella MF, Virella G. Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Diabetes 1996; 45 (suppl 3): S40-S44.
53. Lopes-Virella MF, Mironova M, Virella G. LDL-containing immune complexes and atherosclerosis in diabetes. Diabetes Rev 1997; 5: 410-24.
54. Kobayashi K, Watanabe J, Umeda F, et al. Metabolism of oxidized glycated LDL in cultured bovine aortic endothelial cells. Horm Metab Res 1995; 27: 356-62.
55. Bagdade JD. HDL and reverse cholesterol transport in diabetes. Diabetes Rev 1997; 5: 392-409.
56. Witztum JL, Fisher M, Pietro T, Steinbrecher UP, Elam RL. Nonenzymatic glucosylation of HDL accelerates its catabolism in guinea pigs. Diabetes 1982; 31: 1029-32.
57. Calvo C, Talussot C, Ponsin G, Berthezene F. Non enzymatic glycation of apolipoprotein A1. Effects on its self-association and lipid binding properties. Biochem Biophys Res Commun 1988; 153: 1060-7.
58. 1 with HDL. Eur J Clin Chem Clin Biochem 1992; 30: 3-5.
59. Oram JF, Mendez AJ, Slotte JP, Johnson TF. HDL apolipoproteins mediate removal of sterol from intracellular pools but not from plasma membranes of cholesterol-loaded fibroblasts. Arterioscler Thromb 1991; 11: 403-14.
60. Duell PB, Oram JF, Bierman EL. Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes 1991; 40: 377-84.
61. Rashduni DL, Rifici VA, Schneider SH, Khachadurian AK. Glycation of HDL does not increase its susceptibility to oxidation or diminish its cholesterol efflux capacity. Metabolism 1999; 48: 139-43.
62. 1-containing particles and reverse cholesterol transport in IDDM. Diabetes 1992; 41 (suppl 2): 81-5.
63. Fournier N, Myara I, Atger V, Moatti N. Reactivity of lecithin-cholesterol acyl transferase (LCAT) towards glycated-HDL. Clin Chim Acta 1995; 234: 47-61.
64. 1. Eur J Clin Chem Clin Biochem 1993; 31: 217-20.
65. Swenson ThL. The role of the cholesteryl ester transfer protein in lipoprotein metabolism. Diabetes Metab Rev 1991; 7: 139-53.
66. Mamo JC, Szeto L, Steiner G. Glycation of VLDL from rat plasma impairs its calabolism. Diabetologia 1990; 33: 339-45.
67. Saheki S, Shishino K, Hitsumoto Y, Murase M, Takeuchi N, Uchida K. Decreased susceptibility of glycated VLDL to lipoprotein lipase in vitro and prevention by glutathione. J Atheroscler Thromb 1994; 1: 8-14.
68. Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sutfate proteoglycans and apolipoprotein E. J Lipid Res 1999; 40: 1-16.
69. Shuvaev VV, Fujii J, Kawasaki Y, et al. Glycation of apolipoprotein E impairs its binding to heparin: identification of the major glycation site. Biochim Biophys Acta 1999; 1454: 296-308.